Nohla Therapeutics President and CEO, Katie Fanning, to Present at 2017 Life Science Innovation Northwest Conference

SEATTLE, May 16, 2017 (GLOBE NEWSWIRE) -- Nohla Therapeutics Inc. (Nohla), a leading innovator in the development of off-the-shelf universal donor cellular therapies, announced today that Katie Fanning, the company’s president and CEO, will present at the 2017 Life Science Innovation Northwest Conference being held on May 23 and 24 at the Washington State Convention Center in Seattle. Ms. Fanning’s presentation will include an overview of the company’s technology platform, clinical progress, strategic vision, and near term milestones.

Ms. Fanning is scheduled to present on Tuesday, May 23, 2017 at 11:10 a.m. PDT at the Washington State Convention Center in room 618.

Ms. Fanning joined Nohla in February 2017 bringing over 30 years of industry experience holding previous leadership roles in both public and private biopharmaceutical companies. Having most recently served as Chief Operating Officer at VentiRx Pharmaceuticals, Ms. Fanning played an instrumental role in the strategic collaboration between VentiRx and Celgene Corporation.

Life Science Innovation Northwest is the largest annual life science conference in the Pacific Northwest. With more than 500 attendees, the conference offers networking and professional development for researchers and leaders at all stages. This year’s conference will include panel discussions on antimicrobial resistance, precision medicine, data collaboration, philanthrocapitalism, early-stage company investing, digital health, and federal policy. For more information, please visit

About Nohla

Nohla is a clinical stage company dedicated to the development of universal donor cellular therapies for the treatment of patients with blood cancers and other life threatening conditions. The Company is leveraging a platform developed over two decades of preclinical and clinical research, which enables the ex vivo expansion and directed differentiation of stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching).

Nohla is evaluating the ability of the first of these “off-the-shelf” products to reduce infection and other complications of neutropenia in two lead programs involving multi-center, randomized clinical trials: a Phase 2b study in the setting of cord blood transplant and a global Phase 2 study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML). 


Contact Data